翰思艾泰-B：截至2026年6月30日止六个月的中期业绩公告

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 3378 2026630 20266302026202563020251215 (FIC)(IO)(ADC) (MOA)VersatiBody™autoRx40™ 2026630 • oIIHX009oIaHX111HX044oFICHX009HX044FIC ADC (HX111) •INDBsAb-ADCHX116FDAIND 2026630 HX009 HX009PD-1/SIRPHX009PD-1PD-1CD8+T(TIL-Teff)TIL-TeffPD-1CD47 • 2026HX009 EBV+NHLEBVEBVEBV+NHLPD-L1CD47HX009EBV+NHLEBV+DLBCLHX009EBV+DLBCLIICDECDE 2026630HX009-I-01IbA2019-202450%Tang et al. 2024 Si et al. 2019,2022 Chen et al. 202415%10%7580%Tang et al.2020,2021Si et al. 2019 18A.08(3)HX009 HX111 HX111(ADC)(FIC)OX40-ADCOX40+(MOA) OX40ATLAITL NK/T(TAA)HX111 (TME)T(TIL-Treg)TIL-TregOX40TIL-TregHX111HX111TIL-TregPD-(L)1 • 2026HX111I2026 2026HX111 • HX111PD-1I2026IND 18A.08(3)HX111 HX044 HX044CTLA4CD47(BsAb)PD-1CTLA-4-SIRP(TME)HX044CTLA4 • HX044HX044-I-01I/IIaHX044202634819 • HX008+HX044ICIHX04420267 2026HX044 18A.08(3)HX044 HX116 HX116PD-L1VEGF(BsAb)-(ADC)PD-1 PD-(L)1VEGF BsAb(ICI)PD-(L)1(PFS)BsAbADCBsAb-ADC HX116ADC(ICD)OS HX116PD-L1VEGFADC(DLT) 2026630INDFDAINDFDAIND 18A.08(3)HX116 VersatiBody™autoRx40™ VersatiBody™(BsAb)ADC—MOAHX116— autoRx40™THX011AHX138SLET1D 20256305.3421.0%27.6 2025630(i)(ii)(iii)(iv)(v)(vi)(vii)(viii)(ix) 63020262025 202563031.316.6%26.12026 202563027.923.8(i)(ii)(iii)(iv)(v)(vi)(vii)(viii)(ix) 202563023.817.1%27.92026 202512232025 202563020256305.581.8%1.020251223 33.2202563033.7 2026630500.320251231614.418.6% 2026630610.532.9 100%2025123120.0%202663019.3% 817,768840,362 686,031747,619 1 201412191A82024116 20251223 2.1 202663020251231 2.2 20251231 97 179107 11 (a)9720261231 (b)97 (c)—111779107 3 27,6145,300 5 6 16.5%202516.5%2,000,00020252,000,0008.25%20258.25%16.5%202516.5% 25% 25% 21%8.25%11.5% 7 20262025630202411 (a)20199(i)350,000,000(ii)PD-14.375%40%20251231 252,140,00020251231247,284,00016,303,000PD-120254.375%1 (b) 10 1030 11 1030 20251223HHC1 C3 1,695,600H48,101,27020266301,695,600H 20262122026624 2026630 20266306031.47 H20251223H531.3 2030 20266302026630 2026630 (www.hkexnews.hk)(www.hanxbio.com) 2026630 2026817 (i)(ii)(iii)